Navigation Links
SynCardia's Total Artificial Heart Rescues LVAD Patient with Right Ventricular Failure
Date:9/21/2011

TUCSON, Ariz., Sept. 21, 2011 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the SynCardia temporary Total Artificial Heart, announced today that University Hospital of Nantes successfully transplanted 51-year-old Total Artificial Heart patient Louise Mouche after 177 days of support. Mrs. Mouche is a French gypsy who lives with a sedentary group of people approximately 40 km from Nantes.

"We first implanted Mrs. Mouche with a left ventricular assist device (LVAD)," said Prof. Daniel Duveau, Medical Director of the Thorax Institute at University Hospital of Nantes. "However, a few days later, we removed the LVAD because of right ventricular failure and implanted SynCardia's Total Artificial Heart."

Mrs. Mouche was implanted with SynCardia's Total Artificial Heart on Jan. 30, 2011. While supported by the Total Artificial Heart, she was able to exercise several times a day, riding the exercise bike regularly for 30 to 45 minutes at a time.

On April 24, 2011, Mrs. Mouche was switched to the Freedom® portable driver, a wearable power supply for SynCardia's Total Artificial Heart. Three months later, on July 26, 2011, Mrs. Mouche received her matching donor heart. Post-transplant, she was extubated quickly and transferred out of the ICU 8 days later. One month after her transplant, Mrs. Mouche was discharged home with her new donor heart. Today, she is doing very well and participating in a cardiac rehabilitation program.

"SynCardia's Total Artificial Heart is a very good device with which we have had a lot of successful experiences," said Prof. Duveau. "It is easy to implant, easy to use and very powerful. The Total Artificial Heart is, in our practice, the best and most efficient device in cases of biventricular failure as reported in a non-randomized study in which we compared the Total Artificial Heart and external biventricular support."

University Hospital of Nantes has been implanting the Total Artificial Heart since 1988. The hospital has achieved a 75% bridge to transplant rate with the Total Artificial Heart. Five-year and 10-year survival rates after transplantation among this group of patients are 81% and 76% respectively.

SynCardia recognizes and thanks IST Cardiology, the French distributor for the Total Artificial Heart, for their commitment and on-going support of University Hospital of Nantes.

CAUTION – The Freedom® portable driver is an investigational device, limited by United States law to investigational use.

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the Total is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. More than 950 implants account for more than 230 patient years of life.

Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end-stage biventricular failure. The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through both ventricles. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

In March 2011, Fast Company magazine ranked SynCardia #20 among the World's 50 Most Innovative Companies "for giving mobility to artificial heart recipients." Also in March, the longest running health and wellness series on public television, "Healthy Body, Healthy Mind," produced a 30-minute program featuring SynCardia's Total Artificial Heart. View here

For additional information, please visit: http://www.syncardia.com

Like SynCardia on Facebook

Follow SynCardia on Twitter – @SynCardia

Connect with SynCardia on LinkedIn


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Cell movements totally modular, Stanford study shows
2. NYU Langone Medical Center awarded NIH grants totaling $1,560,000
3. Kent State University professors focus research on the environment with grants totaling $890,000
4. New study quantifies total costs of fragility fractures in 6 major European countries
5. BGI develops RNA-Seq (Quantification) from as low as 100 Ng total RNA
6. Taking the next step toward advanced artificial limbs
7. Researchers design artificial cells that could power medical implants
8. Evolved Machines Selected as a Prime Contractor for DARPA Program to Engineer an Artificial Olfaction System
9. Scientists identify cell changes leading to impaired artificial kidney function
10. Biomedical researchers create artificial human bone marrow in a test tube
11. TECNALIA uses artificial vision to improve recycling of electronic scrap metal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... ... on what they believe could be a new and helpful biomarker for malignant ... Click here to read it now. , Biomarkers are components in ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology: